Insulin resistance–metabolic syndrome patients have been reported to benefit from strategies concerning stimulation of VSMC survival and reduction in FKN/CX3CR1 signaling to promote plaque stability through an IRS2-dependent signaling [34]. The gene discussed is CX3CR1; the disease is Insulin resistance.